论文部分内容阅读
[目的]探讨过氧化物酶体增殖物激活受体γ(PPAR-γ)配体罗格列酮(RGZ)对人卵巢浆液性乳头状囊腺癌SKOV3细胞的抑制作用。[方法]建立卵巢癌SKOV3细胞裸鼠移植瘤模型,观察不同剂量RGZ对移植瘤体积的影响;HE染色观察各组移植瘤组织细胞形态学变化;免疫细胞化学法观察移植瘤中Bcl-2、Cytochrome C蛋白表达水平。[结果]RGZ组(4mg/kg,12mg/kg,60mg/kg,120mg/kg)裸鼠移植瘤体积分别为0.190±0.023mm3、0.065±0.003mm3、0.195±0.004mm3和0.182±0.023mm3,较对照组(0.300±0.016mm3)均明显缩小,差异有统计学意义(P<0.05)。抑瘤率分别为36.7%、78.3%、35.0%和40.0%。HE染色观察RGZ作用SKOV3细胞后有变性细胞、单细胞死亡及大面积的凝固性坏死。Bcl-2在RGZ组(60mg/kg,120mg/kg)中的表达较对照组显著下调,Cytochrome C在RGZ组(60mg/kg,120mg/kg)中的表达较对照组显著上调,差异均有统计学意义(P<0.05)。[结论]RGZ对卵巢癌裸鼠移植瘤有明显抑制作用,可促进凋亡。提示PPAR-γ可能成为卵巢癌治疗的新分子靶点。
[Objective] To investigate the inhibitory effect of peroxisome proliferator-activated receptor γ (PPAR-γ) ligand rosiglitazone (RGZ) on human ovarian serous papillary cystadenocarcinoma SKOV3 cells. [Methods] The ovarian cancer SKOV3 cells in nude mice transplantation model was established to observe the effects of different doses of RGZ on the volume of tumor xenografts; morphological changes of the transplanted tumor tissue were observed by HE staining; the expression of Bcl-2, Cytochrome C protein expression levels. [Results] The tumor volume of RGZ group (4mg / kg, 12mg / kg, 60mg / kg and 120mg / kg) were 0.190 ± 0.023mm3, 0.065 ± 0.003mm3, 0.195 ± 0.004mm3 and 0.182 ± 0.023mm3, respectively The control group (0.300 ± 0.016mm3) were significantly reduced, the difference was statistically significant (P <0.05). The tumor inhibition rates were 36.7%, 78.3%, 35.0% and 40.0%, respectively. HE stain was used to observe the effects of RGZ on SKOV3 cells after degeneration, single cell death and large area coagulation necrosis. The expression of Bcl-2 in RGZ group (60mg / kg, 120mg / kg) was significantly lower than that in control group. The expression of Cytochrome C in RGZ group (60mg / kg, 120mg / kg) Statistical significance (P <0.05). [Conclusion] RGZ can inhibit ovarian cancer xenografts in nude mice and promote apoptosis. Tip PPAR-γ may become a new molecular target for the treatment of ovarian cancer.